Harmony Biosciences Holdings, Inc. (HRMY) Dividend History

Company News

• Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight

  The Developmental and Epileptic Encephalopathies (DEE) market is expected to grow significantly due to approved medications like EPIDIOLEX, rising demand for novel treatments, and the introduction of potential emerging therapies. However, the discontinuation of emerging therapies may impede this growth.

  GlobeNewswire Inc.
• 5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

  The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.

  GlobeNewswire Inc.

  Featured Companies: ATAI CYBN MNMD RVPH
• Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight

  The article discusses the prevalence and impact of rare genetic disorders, which affect over 350 million people worldwide. It highlights the challenges in treating these conditions, including limited treatment options and underfunding for research. The article also provides an overview of the market analysis for various rare genetic disorders, including Usher Syndrome, Alport Syndrome, Menkes Disease, and others.

  GlobeNewswire Inc.

  Featured Companies: AMGN BEAM KRYS RARE SWTX WVE
• Dravet Syndrome Drug Pipeline Research Report 2024: Therapeutic Assessment, Emerging Drugs, Pipeline Development Activities, Competitive Landscape

  The report provides insights into the Dravet Syndrome drug pipeline, including emerging drugs, therapeutic assessment, and the competitive landscape. It highlights the ongoing research and development activities by various companies and academics to address the challenges and seek opportunities in Dravet Syndrome treatment.

  GlobeNewswire Inc.
• Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates

  Harmony Biosciences Holdings, Inc. (HRMY) reported better-than-expected earnings and revenue for the second quarter of 2024. However, the company's stock has underperformed the market so far this year, and the earnings outlook is unfavorable, leading to a Zacks Rank #5 (Strong Sell) rating.

  Zacks Investment Research

  Featured Companies: FATE